Treatment with clobetasol propionate 0.025% topical therapy in various dermatoses
DOI:
https://doi.org/10.18203/2320-6012.ijrms20215061Keywords:
CP 0.025%, Plaque psoriasis, Psoriasis, TCsAbstract
Owing to their anti-inflammatory and vasoconstrictive properties. Topical corticosteroids (TCs) provide benefits in various dermatological conditions, including atopic eczema, psoriasis, chronic hand eczema, and localized vitiligo. Clobetasol propionate (CP) is the most common topical agent possessing anti-inflammatory, antimitotic, antipruritic, and immunosuppressive properties that are employed in the management of plaque psoriasis. CP 0.025% cream was approved by the United States food and drug administration for the treatment of moderate-to-severe psoriasis in adult patients. The formulation is free from known contact allergens, such as propylene glycol, short-chain alcohols, and sorbitol-based emulsifiers, and has demonstrated hypoallergenic effects. High penetration of active ingredients and a lower degree of systemic absorption make CP 0.025% an effective and safe agent. This case series discusses the clinical experience of using CP 0.025% cream in various dermatologic conditions, focusing on its efficacy and safety.
References
Del Rosso JQ. Topical corticosteroid therapy for psoriasis-a review of clobetasol propionate 0.025% cream and the clinical relevance of penetration modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.
Uva L, Miguel D, Pinheiro C. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012;561018.
Zampetti A, Feliciani C, Tulli A. Pharmacotherapy of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses focus on clobetasol propionate. Clin Med Insights Ther. 2010;2:523-37.
Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of non-scalp regions. J Cutan Med Surg. 2003;7(3):185-92.
Draelos ZD, Fowler JF, Cornelison R. A randomized, parallel group, open label, multicenter study to assess the potential for adrenal suppression and systemic drug absorption following multiple dosing with clobetasol propionate cream (Impoyz™), 0.025% versus clobetasol propionate (Temovate®). J Cutan Med Surg. 2018;2(6):410-20.